Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholecystitis, Acute | 5 | 2019 | 28 | 1.820 |
Why?
|
| Medicaid | 3 | 2020 | 352 | 1.540 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 1.270 |
Why?
|
| Laparoscopy | 3 | 2021 | 401 | 1.110 |
Why?
|
| Appendectomy | 3 | 2021 | 50 | 0.930 |
Why?
|
| Appendicitis | 4 | 2021 | 75 | 0.910 |
Why?
|
| General Surgery | 4 | 2024 | 193 | 0.870 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.850 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 2014 | 46 | 0.840 |
Why?
|
| Cholecystostomy | 4 | 2016 | 20 | 0.830 |
Why?
|
| Orbital Fractures | 2 | 2020 | 7 | 0.830 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2022 | 4 | 0.790 |
Why?
|
| Occupational Injuries | 1 | 2022 | 37 | 0.790 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 17 | 0.780 |
Why?
|
| Hematoma, Subdural | 1 | 2021 | 9 | 0.770 |
Why?
|
| Length of Stay | 7 | 2024 | 782 | 0.740 |
Why?
|
| Insurance Coverage | 1 | 2021 | 98 | 0.730 |
Why?
|
| Critical Care | 3 | 2016 | 418 | 0.720 |
Why?
|
| Intestine, Small | 2 | 2018 | 75 | 0.710 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 142 | 0.710 |
Why?
|
| Hemostasis | 1 | 2020 | 20 | 0.700 |
Why?
|
| Clinical Clerkship | 2 | 2011 | 89 | 0.700 |
Why?
|
| Fracture Fixation | 1 | 2020 | 16 | 0.690 |
Why?
|
| Pulmonary Embolism | 2 | 2022 | 171 | 0.680 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 139 | 0.670 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 251 | 0.640 |
Why?
|
| Trauma Centers | 1 | 2020 | 119 | 0.630 |
Why?
|
| Retrospective Studies | 16 | 2024 | 6147 | 0.630 |
Why?
|
| Curriculum | 3 | 2011 | 569 | 0.610 |
Why?
|
| Intestinal Obstruction | 2 | 2018 | 50 | 0.590 |
Why?
|
| Intestinal Diseases | 1 | 2018 | 34 | 0.570 |
Why?
|
| Abdominal Pain | 1 | 2018 | 94 | 0.560 |
Why?
|
| Blood Coagulation | 1 | 2017 | 39 | 0.560 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 86 | 0.550 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 332 | 0.500 |
Why?
|
| Adult | 17 | 2024 | 15972 | 0.490 |
Why?
|
| Male | 26 | 2024 | 27949 | 0.460 |
Why?
|
| MicroRNAs | 1 | 2020 | 617 | 0.450 |
Why?
|
| Humans | 37 | 2024 | 60081 | 0.440 |
Why?
|
| Teaching | 2 | 2011 | 157 | 0.430 |
Why?
|
| Intraabdominal Infections | 1 | 2013 | 2 | 0.420 |
Why?
|
| Female | 24 | 2024 | 31224 | 0.420 |
Why?
|
| United States | 9 | 2022 | 7620 | 0.390 |
Why?
|
| Students, Medical | 2 | 2011 | 246 | 0.370 |
Why?
|
| Culture | 1 | 2011 | 76 | 0.360 |
Why?
|
| Postoperative Complications | 5 | 2016 | 1175 | 0.350 |
Why?
|
| Career Choice | 1 | 2011 | 114 | 0.340 |
Why?
|
| Middle Aged | 14 | 2024 | 16540 | 0.340 |
Why?
|
| Multiple Trauma | 2 | 2007 | 27 | 0.330 |
Why?
|
| Aortic Diseases | 2 | 2000 | 67 | 0.330 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 100 | 0.320 |
Why?
|
| Communication | 2 | 2010 | 560 | 0.320 |
Why?
|
| Intensive Care Units | 1 | 2013 | 454 | 0.310 |
Why?
|
| Gallbladder Diseases | 1 | 2008 | 26 | 0.310 |
Why?
|
| Seasons | 2 | 2020 | 130 | 0.310 |
Why?
|
| Embolism, Air | 1 | 2007 | 9 | 0.290 |
Why?
|
| Physician-Patient Relations | 2 | 2010 | 397 | 0.290 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 104 | 0.280 |
Why?
|
| Massachusetts | 3 | 2020 | 2119 | 0.280 |
Why?
|
| Omeprazole | 1 | 2006 | 4 | 0.270 |
Why?
|
| Gallbladder | 1 | 2006 | 31 | 0.260 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 38 | 0.260 |
Why?
|
| Aged | 13 | 2019 | 13594 | 0.240 |
Why?
|
| Gravity Suits | 2 | 2002 | 2 | 0.230 |
Why?
|
| Fibrinolysis | 2 | 2002 | 5 | 0.230 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 345 | 0.230 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 1038 | 0.220 |
Why?
|
| Farmers | 1 | 2022 | 18 | 0.200 |
Why?
|
| Reaction Time | 1 | 2022 | 119 | 0.200 |
Why?
|
| Academic Medical Centers | 3 | 2021 | 317 | 0.190 |
Why?
|
| Upper Extremity | 1 | 2022 | 49 | 0.190 |
Why?
|
| Internship and Residency | 2 | 2024 | 748 | 0.190 |
Why?
|
| Glasgow Coma Scale | 1 | 2021 | 44 | 0.190 |
Why?
|
| Risk Factors | 4 | 2022 | 5090 | 0.190 |
Why?
|
| Injury Severity Score | 1 | 2021 | 102 | 0.190 |
Why?
|
| Thrombophlebitis | 1 | 2000 | 16 | 0.180 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2000 | 33 | 0.170 |
Why?
|
| Alcoholic Intoxication | 1 | 2020 | 27 | 0.170 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2011 | 152 | 0.160 |
Why?
|
| Libraries, Medical | 2 | 1990 | 11 | 0.160 |
Why?
|
| Up-Regulation | 1 | 2020 | 365 | 0.160 |
Why?
|
| Obesity | 2 | 2022 | 1191 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2020 | 195 | 0.160 |
Why?
|
| Intermittent Claudication | 1 | 1999 | 50 | 0.160 |
Why?
|
| Carotid Stenosis | 1 | 1999 | 105 | 0.150 |
Why?
|
| Gene Silencing | 1 | 2020 | 379 | 0.150 |
Why?
|
| Gastrointestinal Diseases | 2 | 2010 | 77 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 735 | 0.140 |
Why?
|
| Capsule Endoscopy | 1 | 2018 | 38 | 0.140 |
Why?
|
| Clinical Competence | 3 | 2011 | 699 | 0.140 |
Why?
|
| Walking | 1 | 1999 | 230 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2018 | 117 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 792 | 0.140 |
Why?
|
| Paclitaxel | 2 | 1994 | 91 | 0.130 |
Why?
|
| Anemia | 1 | 2018 | 118 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 1099 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2016 | 64 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1387 | 0.130 |
Why?
|
| Recurrence | 1 | 2018 | 600 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2019 | 483 | 0.130 |
Why?
|
| Medicare | 1 | 2019 | 603 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 856 | 0.120 |
Why?
|
| Critical Illness | 2 | 2016 | 342 | 0.120 |
Why?
|
| Vena Cava Filters | 2 | 2009 | 21 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2010 | 576 | 0.120 |
Why?
|
| Cholecystectomy | 1 | 2014 | 31 | 0.120 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 5200 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2018 | 409 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2014 | 5264 | 0.110 |
Why?
|
| Smoking | 1 | 1999 | 837 | 0.110 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2013 | 5 | 0.110 |
Why?
|
| Patient Safety | 1 | 2016 | 245 | 0.110 |
Why?
|
| Appendiceal Neoplasms | 1 | 2013 | 8 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2013 | 30 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 1481 | 0.110 |
Why?
|
| Animals | 6 | 2020 | 19739 | 0.100 |
Why?
|
| Young Adult | 3 | 2019 | 4398 | 0.100 |
Why?
|
| MEDLARS | 2 | 1990 | 3 | 0.100 |
Why?
|
| Educational Measurement | 2 | 2010 | 213 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 1992 | 44 | 0.090 |
Why?
|
| Cross Infection | 1 | 2013 | 154 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 61 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2505 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 108 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 1994 | 306 | 0.090 |
Why?
|
| Intubation | 1 | 2010 | 11 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2010 | 930 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2010 | 257 | 0.090 |
Why?
|
| Empathy | 1 | 2010 | 67 | 0.090 |
Why?
|
| Computer User Training | 1 | 1990 | 7 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 242 | 0.080 |
Why?
|
| Patient Simulation | 1 | 2010 | 67 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2010 | 128 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 134 | 0.080 |
Why?
|
| Thrombophilia | 1 | 2009 | 15 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Duplex | 2 | 1999 | 46 | 0.080 |
Why?
|
| Decision Making | 1 | 2013 | 394 | 0.080 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1999 | 67 | 0.080 |
Why?
|
| Algorithms | 1 | 2014 | 1006 | 0.080 |
Why?
|
| Bariatric Surgery | 1 | 2009 | 53 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2014 | 3133 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 774 | 0.080 |
Why?
|
| Databases, Factual | 1 | 1992 | 850 | 0.070 |
Why?
|
| Gastric Bypass | 1 | 2009 | 74 | 0.070 |
Why?
|
| Emotions | 1 | 2010 | 218 | 0.070 |
Why?
|
| Stents | 1 | 2011 | 459 | 0.070 |
Why?
|
| Radiography | 2 | 2007 | 514 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 115 | 0.070 |
Why?
|
| Judaism | 1 | 1986 | 1 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 2615 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 568 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 319 | 0.060 |
Why?
|
| Ethics, Medical | 1 | 1986 | 38 | 0.060 |
Why?
|
| Movement | 1 | 2006 | 147 | 0.060 |
Why?
|
| Maryland | 1 | 2024 | 33 | 0.060 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 2 | 2002 | 15 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2002 | 125 | 0.050 |
Why?
|
| Glioma | 2 | 1994 | 102 | 0.050 |
Why?
|
| Pressure | 1 | 2002 | 75 | 0.050 |
Why?
|
| Age Factors | 2 | 2013 | 1527 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 319 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 107 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 2360 | 0.050 |
Why?
|
| Prevalence | 2 | 2009 | 1299 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 1565 | 0.050 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1999 | 45 | 0.040 |
Why?
|
| Carotid Artery, Internal | 1 | 1999 | 66 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 1999 | 71 | 0.040 |
Why?
|
| Body Composition | 1 | 1999 | 155 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 92 | 0.040 |
Why?
|
| Aortic Aneurysm | 1 | 1999 | 84 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 220 | 0.040 |
Why?
|
| Perception | 1 | 1999 | 179 | 0.040 |
Why?
|
| Hemodynamics | 1 | 1999 | 236 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 928 | 0.030 |
Why?
|
| Diplopia | 1 | 1996 | 10 | 0.030 |
Why?
|
| Blood Pressure | 1 | 1999 | 522 | 0.030 |
Why?
|
| Motor Activity | 1 | 1999 | 343 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1100 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1996 | 83 | 0.030 |
Why?
|
| Rats | 3 | 1994 | 1908 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 151 | 0.030 |
Why?
|
| Accidental Falls | 1 | 1996 | 154 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1994 | 16 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1994 | 81 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 1994 | 9 | 0.030 |
Why?
|
| Medulloblastoma | 1 | 1994 | 11 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 1994 | 38 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2480 | 0.030 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 14 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 453 | 0.030 |
Why?
|
| Grateful Med | 1 | 1992 | 1 | 0.020 |
Why?
|
| Cholecystography | 1 | 2011 | 14 | 0.020 |
Why?
|
| MEDLINE | 1 | 1992 | 19 | 0.020 |
Why?
|
| Cell Movement | 1 | 1994 | 426 | 0.020 |
Why?
|
| Catheterization | 1 | 2011 | 111 | 0.020 |
Why?
|
| Education, Nursing, Graduate | 1 | 2011 | 48 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2010 | 21 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 1994 | 466 | 0.020 |
Why?
|
| Cholecystitis | 1 | 2010 | 29 | 0.020 |
Why?
|
| Diverticulitis | 1 | 2010 | 28 | 0.020 |
Why?
|
| Abdomen, Acute | 1 | 2010 | 24 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 199 | 0.020 |
Why?
|
| Baltimore | 1 | 1990 | 18 | 0.020 |
Why?
|
| Consultants | 1 | 1990 | 12 | 0.020 |
Why?
|
| Herniorrhaphy | 1 | 2010 | 65 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1267 | 0.020 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 1989 | 4 | 0.020 |
Why?
|
| Brain | 2 | 1994 | 1485 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 104 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 488 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 661 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 177 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 453 | 0.020 |
Why?
|
| Fees, Medical | 1 | 1986 | 1 | 0.020 |
Why?
|
| Autopsy | 1 | 1986 | 46 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1986 | 13 | 0.020 |
Why?
|
| Abortion, Induced | 1 | 1986 | 24 | 0.020 |
Why?
|
| Software | 1 | 1989 | 376 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 892 | 0.020 |
Why?
|
| Patient Care | 1 | 1986 | 78 | 0.020 |
Why?
|
| Cesarean Section | 1 | 1986 | 97 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 1140 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 1986 | 122 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 5944 | 0.010 |
Why?
|
| Leg | 1 | 2002 | 84 | 0.010 |
Why?
|
| Abdomen | 1 | 2002 | 92 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1936 | 0.010 |
Why?
|
| Heparin | 1 | 2002 | 111 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1986 | 1315 | 0.010 |
Why?
|
| Immobilization | 1 | 1999 | 12 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1999 | 25 | 0.010 |
Why?
|
| Renal Artery | 1 | 1999 | 29 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 1999 | 27 | 0.010 |
Why?
|
| Catheterization, Peripheral | 1 | 1999 | 46 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1999 | 132 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 170 | 0.010 |
Why?
|
| Titanium | 1 | 1999 | 58 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 205 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1999 | 150 | 0.010 |
Why?
|
| Patient Transfer | 1 | 1999 | 91 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 489 | 0.010 |
Why?
|
| Equipment Design | 1 | 1999 | 319 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 1999 | 295 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 1994 | 39 | 0.010 |
Why?
|
| Decanoic Acids | 1 | 1994 | 2 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 1994 | 110 | 0.010 |
Why?
|
| Drug Implants | 1 | 1994 | 15 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1994 | 23 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 52 | 0.010 |
Why?
|
| Microcirculation | 1 | 1994 | 51 | 0.010 |
Why?
|
| Fluorescence | 1 | 1994 | 83 | 0.010 |
Why?
|
| Polyesters | 1 | 1994 | 47 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1994 | 108 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 1994 | 244 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1994 | 284 | 0.010 |
Why?
|
| Central Nervous System Diseases | 1 | 1994 | 56 | 0.010 |
Why?
|
| Biopolymers | 1 | 1994 | 70 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1994 | 171 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1994 | 399 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1994 | 558 | 0.010 |
Why?
|
| Neoplasms | 1 | 2002 | 1262 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1994 | 684 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 876 | 0.010 |
Why?
|
| Mice | 1 | 1994 | 10317 | 0.000 |
Why?
|